Reading the tape
NASDAQ: AMRX
Amneal Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Market Cap
$4.11B
52w High
$15.42
52w Low
$7.02
P/E
95.96
Volume
1.84M
Outstanding Shares
319.00M
Price vs Fundamentals
Why The Stock Is Moving
Momentum disconnected from fundamentalsHigh confidence
1Y Price: 68.02%Revenue (TTM): -17.91%FCF (TTM): 7.29%P/FCF: 83rd pct
What changed
The stock rose 68.02% over the last year. Revenue declined 17.91% over the trailing twelve months. Operating margin moved from 12.73% to 9.72%. Free cash flow grew 7.29% over the trailing twelve months.
What the market seems to be pricing
The stock is rising despite deteriorating fundamentals and now sits at the 83rd percentile of its historical P/FCF range. This is a momentum-driven move — the market may be front-running a recovery that has not yet appeared in reported numbers.
What would invalidate this read
Operating margin (currently 9.72%) would need to stabilize or improve to justify the move. Revenue is declining 17.91% — a trend reversal in the next report would be the key signal to watch. This read is wrong if the next period shows operating metrics turning the corner. At that point the price would be anticipating real improvement rather than running ahead of it.
Company profile
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.
CEOChirag K. Patel
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees8,300
IPO dateMay 7, 2018
Valuation
Forward P/E—
EV/EBITDA10.56
Enterprise value$6.37B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-100%
Gross margin36.9%▲3.04%vs FY2024
Operating margin9.72%▲57.06%vs FY2024
ROE-101.78%▼195.15%vs FY2024
Analyst consensus
RatingBuy
Target price$17.00▲32.09%
10
Buy
6
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 1, 2026
Q2 FY26 · EPS est $0.17 · Revenue est $719.66M
View